Key Summary Points {#FPar1}
==================

**Why carry out this study?**The Global Initiative for Chronic Obstructive Lung Disease recommends long-acting muscarinic antagonists (LAMAs) or long-acting β~2~-agonists (LABAs) as first-line treatment for patients with chronic obstructive pulmonary disease (COPD), with escalation to dual-bronchodilator therapy as the next step; however, the American Thoracic Society recommends dual LAMA/LABA bronchodilator therapy over LAMA or LABA monotherapy in patients with COPD who experience dyspnoea or exercise intolerance. The National Institute for Health and Care excellence recommends dual LAMA/LABA therapy for patients with no indication of asthmatic features or corticosteroid responsiveness, who remain breathless or have exacerbations despite optimised non-pharmacological management and use of short-acting bronchodilators.Previous studies comparing combined LAMA/LABA treatment with LAMA or LABA alone included patients on a range of background therapies, making it difficult to assess the clinical benefit of treatment escalation.**What was learned from the study?**This pooled analysis, which focused specifically on patients with moderate-to-severe COPD treated with LAMA monotherapy at baseline, showed significantly greater improvements in lung function, health status and breathlessness when treatment was escalated to dual bronchodilation with tiotropium/olodaterol compared with tiotropium alone.More patients showed a clinically relevant improvement in at least one of the analysed categories (forced expiratory volume in 1 s, St. George's Respiratory Questionnaire or Transition Dyspnoea Index) when treated with tiotropium/olodaterol (87.7%) compared with tiotropium (74.5%).This study supports the benefits of therapy optimisation to dual bronchodilation with tiotropium/olodaterol in patients receiving tiotropium alone.

Introduction {#Sec1}
============

Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity \[[@CR1]--[@CR4]\]. In 2016, COPD was the third leading cause of death worldwide, a trend that is anticipated to continue through 2020 \[[@CR5], [@CR6]\]. Additionally, patients with COPD continue to report reduced quality of life \[[@CR7]\].

The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report recommends a stepwise pharmacological treatment plan for patients with COPD that begins with a long-acting bronchodilator monotherapy (long-acting muscarinic antagonists \[LAMAs\] or long-acting β~2~-agonists \[LABAs\]) as first-line maintenance treatment for most patients, with escalation to dual bronchodilation as the next step \[[@CR8]\]. In line with these recommendations, many patients receive initial treatment with LAMAs or, less commonly, LABAs; despite this, many patients treated with monotherapy remain symptomatic \[[@CR9]--[@CR13]\]. The mechanism of action for LAMAs involves blocking the bronchoconstriction effect of acetylcholine, whereas LABAs relax airway smooth muscle by activating β~2~-receptors \[[@CR9]\]. Therefore, combining these therapies can have complementary and additive effects. Accordingly, the American Thoracic Society 2020 clinical practice guidelines recommend dual LAMA/LABA bronchodilator therapy over LABA or LAMA monotherapy for patients with COPD with dyspnoea or exercise intolerance \[[@CR14]\]. Additionally, the National Institute for Health and Care Excellence recommends dual LAMA/LABA therapy for patients with no indication of asthmatic features or corticosteroid responsiveness, who remain breathless or have exacerbations despite optimised non-pharmacological management and use of short-acting bronchodilators \[[@CR15]\].

Tiotropium, a once-daily LAMA, has been shown to provide long-term improvements in lung function, quality of life and exercise capacity, along with a reduced risk of exacerbations \[[@CR7], [@CR10], [@CR16]\]. Olodaterol, a once-daily LABA with high selectivity for the β~2~-adrenoceptor \[[@CR17]\], has been combined with tiotropium as a dual therapy (tiotropium/olodaterol) for COPD delivered using the Respimat^®^ inhaler \[[@CR2], [@CR10], [@CR17], [@CR18]\]. The combination of tiotropium/olodaterol has been assessed in multiple trials and across different disease severities, demonstrating improvements in lung function, symptoms and quality of life, which has led to its approval for use in many countries worldwide \[[@CR17]--[@CR21]\].

TONADO^®^ 1&2 and OTEMTO^®^ 1&2 were paired, replicate, double-blind, parallel-group, active-controlled, multicentre, randomised, Phase III studies that included patients with moderate-to-severe (OTEMTO) or moderate-to-very-severe (TONADO) COPD \[[@CR10], [@CR22]\]. TONADO previously showed improvements in lung function with acceptable safety profiles over a 52-week period when patients were treated with tiotropium/olodaterol compared with tiotropium or olodaterol monotherapies \[[@CR10]\]. OTEMTO also demonstrated improvements in lung function, with an acceptable safety profile in patients treated with tiotropium/olodaterol compared with tiotropium monotherapy or placebo \[[@CR22]\].

Previous studies comparing LAMA/LABA with their monotherapies included patients on a range of background therapies \[[@CR10], [@CR23]\], making it difficult to truly assess the clinical benefit of treatment escalation from one to two long-acting bronchodilators. In this pooled analysis, we focused specifically on patients with moderate-to-severe COPD treated with LAMA monotherapy at baseline to assess the effects of treatment escalation to dual-bronchodilator therapy on lung function, symptoms and safety profiles \[[@CR10], [@CR22]\].

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

TONADO 1&2 (NCT01431274 and NCT01431287) and OTEMTO 1&2 (NCT01964352 and NCT02006732) study designs have previously been described \[[@CR10], [@CR22]\]. The OTEMTO studies included placebo-controlled and comparator-controlled arms; TONADO did not include a placebo-controlled arm.

The current analysis focuses on patients in these trials who were treated with LAMA monotherapy at baseline and subsequently randomised to receive either 5 µg tiotropium or 5/5 µg tiotropium/olodaterol. Treatments were administered once daily with the Respimat^®^ inhaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany).

The study protocols were reviewed and approved by the Independent Ethics Committees and/or Institutional Review Boards of the participating centres. The studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients in these studies provided written informed consent.

Study Outcomes and Assessments {#Sec4}
------------------------------

Data were pooled from the TONADO and OTEMTO studies after 12 weeks. Here we assess trough forced expiratory volume in 1 s (FEV~1~), St. George's Respiratory Questionnaire (SGRQ) total score and Transitional Dyspnoea Index (TDI) focal scores.

Responder rates for these endpoints were also analysed. Responders for trough FEV~1~ (a change of \> 0.1 l), SGRQ (a decrease of ≥ 4.0 points) and TDI (an increase of ≥ 1.0 point versus baseline at the time of analysis) were defined based on the suggested minimum clinically important difference (MCID) for active treatment compared with placebo \[[@CR10], [@CR24]--[@CR26]\].

The adjusted means were obtained from a mixed effects model for repeated measures, which included the fixed effects of treatment, study (TONADO/OTEMTO combined analysis only), planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction. A logistic regression model with treatment as covariate was fitted for the responder analysis.

Patients {#Sec5}
--------

The inclusion and exclusion criteria for TONADO and OTEMTO have been previously described \[[@CR10], [@CR22]\]. Briefly, patients were aged ≥ 40 years, with a confirmed diagnosis of moderate-to-severe (OTEMTO) or moderate-to-very-severe (TONADO) COPD, post-bronchodilator FEV~1~ \< 80% of predicted normal (lower limit ≥ 30% in OTEMTO; no lower limit specified for TONADO) and post-bronchodilator FEV~1~/forced vital capacity \< 70% of predicted. Patients in these studies were either current or ex-smokers with a smoking history of \> 10 pack-years. Patients were not required to be symptomatic to enter the studies. The current analysis includes only patients receiving LAMA maintenance therapy at study entry; patients were excluded from this analysis if they were on any other COPD maintenance therapy (e.g., inhaled corticosteroid \[ICS\] therapy) at baseline.

Additional subgroup analyses were conducted according to the patient GOLD status; these included GOLD stage 2 and 3 patients, while GOLD stage 4 patients were excluded because of the low number of patients.

Results {#Sec6}
=======

Baseline Characteristics {#Sec7}
------------------------

Baseline characteristics were collected from 299 patients with moderate-to-very-severe COPD treated with LAMA monotherapy only at baseline; patients on any other maintenance therapy (including ICS) were excluded from the current analyses. Of these, 292 (97.7%) were treated with tiotropium at baseline; 6 (2.0%) were treated with glycopyrronium and 1 (0.3%) patient was treated with aclidinium bromide. As shown in Table [1](#Tab1){ref-type="table"}, baseline characteristics were similar between the two treatment arms (tiotropium/olodaterol and tiotropium), with the exception of weight (mean difference − 4.6 ± 2.29 kg) and smoking status (ex-smokers: odds ratio 0.60, 95% confidence interval \[CI\] 0.38--0.96). Additional sensitivity analyses controlling for these covariates did not alter the presented results (data not shown).Table 1Patient characteristics at baselineTiotropium 5 µg (*n* = 151)Tiotropium/olodaterol 5/5 µg (*n* = 148)Male, *n* (%)109 (72.2)99 (66.9)Mean age, years (SD)65.2 (8.0)65.9 (8.7)Weight, kg (SD)\*76.0 (20.6)71.4 (18.9)Smoking history, *n* (%) Never smoked0 (0.0)0 (0.0) Ex-smoker\*97 (64.2)77 (52.0) Current smoker\*54 (35.8)71 (48.0)Smoking pack-years, mean (SD)48.9 (26.8)49.9 (23.6)Pre-bronchodilator spirometry, mean (SD) FEV~1~, l1.3 (0.5)1.3 (0.5) FVC, l2.8 (0.8)2.8 (0.9)Post-bronchodilator spirometry, mean (SD) FEV~1~, l1.5 (0.5)1.4 (0.5) FEV~1~ % predicted54.3 (14.6)54.5 (13.8) FVC, l3.2 (0.9)3.1 (0.8) FEV~1~/FVC,  %47.2 (11.5)47.3 (10.7)SGRQ score39.9 (15.9)37.5 (16.6)BDI score7.0 (2.1)7.2 (1.9)GOLD stage, *n* (%) 1: FEV~1~ ≥ 80%0 (0.0)0 (0.0) 2: FEV~1~ 50-- \< 80%94 (62.3)96 (64.9) 3: FEV~1~ 30-- \< 50%44 (29.1)44 (29.7) 4: FEV~1~ \< 30%13 (8.6)8 (5.4)BDI, baseline dyspnoea index; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation; SGRQ, St. George's Respiratory Questionnaire\*Significant differences (*P* \< 0.05) were identified between the treatment arms, additional sensitivity analyses controlling for weight and smoking status did not affect the results trend for FEV~1~, SGRQ or TDI (data not shown)

Efficacy at Week 12 {#Sec8}
-------------------

### Trough FEV~1~ {#Sec9}

For trough FEV~1~, 291 patients were assessed. At week 12, a mean improvement in trough FEV~1~ from baseline was noted for patients treated with tiotropium/olodaterol (0.159 ± 0.015 l) and those treated with tiotropium (0.085 ± 0.015 l). The adjusted mean difference between tiotropium/olodaterol and tiotropium was 0.074 ± 0.021 l (95% CI 0.033, 0.115; *P* = 0.0004) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1FEV~1~ change from baseline at 12 weeks. The common baseline mean was calculated as 1.219 ± 0.029 l. \**P* = 0.0004 (*P* \< 0.001). CI, confidence interval; FEV~1~, forced expiratory volume in 1 s; SE, standard error; T/O, tiotropium/olodaterol; Tio, tiotropium

### SGRQ {#Sec10}

In total, 283 patients were included in the SGRQ analysis. Patients showed a mean improvement (reduction in score) when treated with tiotropium/olodaterol (− 5.981 ± 0.88 points) or tiotropium monotherapy (− 3.306 ± 0.88 points) (Fig. [2](#Fig2){ref-type="fig"}). The adjusted mean difference between tiotropium/olodaterol and tiotropium was calculated as − 2.675 ± 1.21 points (95% CI − 5.060, − 0.291; *P* = 0.0280).Fig. 2SGRQ change from baseline at 12 weeks. Common baseline mean for SGRQ was 38.74 ± 0.972 points. \**P* = 0.0280 (*P* \< 0.05). CI, confidence interval; SE, standard error; SGRQ, St. George's Respiratory Questionnaire; T/O, tiotropium/olodaterol; Tio, tiotropium

### TDI {#Sec11}

TDI was assessed in 283 patients through the treatment period and compared with baseline dyspnoea index (BDI). At the end of the 12-week treatment period, patients in both treatment arms showed improvement in their dyspnoea index (mean improvement of 1.911 ± 0.21 points for patients treated with tiotropium/olodaterol and 0.763 ± 0.21 points for those treated with tiotropium). The adjusted mean difference between tiotropium/olodaterol and tiotropium was calculated as 1.148 ± 0.30 (95% CI 0.56, 1.73; *P* = 0.0001) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3TDI change from baseline at 12 weeks. At baseline, patients from the TONADO and OTEMTO trials showed a combined baseline mean of 7.138 ± 0.117 points. \**P* = 0.0001. CI, confidence interval; SE, standard error; T/O, tiotropium/olodaterol; TDI, Transition Dyspnoea Index; Tio, tiotropium

Responder Rates {#Sec12}
---------------

### Trough FEV~1~ {#Sec13}

At the end of week 12, more patients treated with tiotropium/olodaterol (*n* = 100; 68.5%) showed a response in trough FEV~1~ (an increase of \> 0.1 l in FEV~1~) than patients treated with tiotropium (*n* = 61; 40.9%) (Fig. [4](#Fig4){ref-type="fig"}). At the end of the 12-week treatment period, the responder odds ratio for FEV~1~ was 3.14 ± 0.77 l (95% CI 1.94, 5.06; *P* \< 0.0001).Fig. 4Assessed responder rates after 12 weeks. \*MCID in at least one of the assessed outcomes (FEV~1~ ≥ 0.1 l, SGRQ ≥ 4.0 points or TDI ≥ 1.0 point). CI, confidence interval; FEV~1~, forced expiratory volume in 1 s; MCID, minimum clinically important difference; SGRQ, St. George's Respiratory Questionnaire; T/O, tiotropium/olodaterol; TDI, Transition Dyspnoea Index; Tio, tiotropium

### SGRQ {#Sec14}

In total, 81 (57.4%) patients treated with tiotropium/olodaterol and 68 (47.9%) patients treated with tiotropium met the SGRQ responder criteria (a decrease of ≥ 4 points in SGRQ) (Fig. [4](#Fig4){ref-type="fig"}). The responder odds ratio for SGRQ score was 1.49 ± 0.36 (95% CI 0.93, 2.40; *P* = 0.0980) when comparing patients treated with tiotropium/olodaterol with patients treated with tiotropium.

### TDI {#Sec15}

Eighty (57.1%) patients treated with tiotropium/olodaterol and 43 (31.5%) patients treated with tiotropium were classed as TDI responders (TDI focal score ≥ 1 point higher than their respective BDI) (Fig. [4](#Fig4){ref-type="fig"}). The overall odds ratio for TDI responders was 2.81 ± 0.71 (95% CI 1.71, 4.60; *P* \< 0.0001).

Patients with MCID {#Sec16}
------------------

Of the overall population, 128 (87.7%) patients treated with tiotropium/olodaterol and 111 (74.5%) patients treated with tiotropium experienced an MCID from baseline in at least one of the analysed outcomes (FEV~1~, SGRQ or TDI). The subjects with at least one MCID from the analysed outcomes after 12 weeks showed an odds ratio of 2.43 ± 0.77 (95% CI 1.32, 4.51; *P* = 0.0046) in favour of tiotropium/olodaterol (Fig. [4](#Fig4){ref-type="fig"}).

### Subgroup Analysis by GOLD Status {#Sec17}

Additionally, patients were analysed for MCID in at least one of the analysed outcomes according to their GOLD stage. This subgroup analysis included a small subpopulation of 186 GOLD stage 2 patients (92 treated with tiotropium and 94 treated with tiotropium/olodaterol). Of these, 80 (85.1%) patients treated with tiotropium/olodaterol and 72 (78.3%) patients treated with tiotropium achieved the MCID in at least one of the analysed outcomes. Similar trends were shown when assessing a small subpopulation of 88 GOLD stage 3 patients, with MCID being achieved in at least one of the analysed outcomes in 40 (90.9%) patients treated with tiotropium/olodaterol and 30 (68.2%) patients treated with tiotropium at the end of the 12-week treatment period (Fig. [5](#Fig5){ref-type="fig"}). The calculated odds ratio was 1.59 ± 0.61 (95% CI 0.75, 3.37; *P* = 0.2295) for GOLD stage 2 and 4.67 ± 2.88 (95% CI 1.40, 15.62; *P* = 0.0124) for GOLD stage 3. GOLD stage 4 patients were omitted from the subgroup analysis because of the low number of patients (13 tiotropium-treated patients and 8 tiotropium/olodaterol-treated patients); however, of the GOLD 4 patients, 9 (69.2%) tiotropium-treated patients and 8 (100.0%) tiotropium/olodaterol-treated patients achieved an MCID in at least one of the analysed outcomes.Fig. 5Subgroup analysis of responder rates by GOLD stage. CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; T/O, tiotropium/olodaterol; TDI, Transition Dyspnoea Index; Tio, tiotropium

Safety {#Sec18}
------

Table [2](#Tab2){ref-type="table"} shows a summary of adverse events (AEs) for the combined data set (studies NCT01431274, NCT01431287, NCT01964352 and NCT02006732). AE incidence was similar between the two treatment arms, with most AEs being mild or moderate. In the tiotropium arm, 71.5% of patients reported at least one AE versus 63.5% of patients in the tiotropium/olodaterol arm. In the two treatment arms, a similar number of patients reported drug-related AEs: six (4.0%) patients in the tiotropium arm and seven (4.7%) patients in the tiotropium/olodaterol arm. Similar rates of serious AEs were reported in the two treatment arms: 18 (11.9%) patients treated with tiotropium and 15 (10.1%) patients treated with tiotropium/olodaterol. One fatal serious AE was reported in the tiotropium/olodaterol arm (0.7% of patients).Table 2Summary of adverse events: combined analysis (treated set)Tiotropium 5 µg (*n* = 151)Tiotropium/olodaterol 5/5 µg (*n* = 148)Patients with: *n* (%) Any AE108 (71.5)94 (63.5) Severe AEs15 (9.9)15 (10.1) Investigator-defined drug-related AEs6 (4.0)7 (4.7) AEs leading to discontinuation10 (6.6)4 (2.7)Patients with serious AEs18 (11.9)15 (10.1) Fatal0 (0.0)1 (0.7) Life-threatening0 (0.0)0 (0.0) Disability/incapacitation1 (0.7)0 (0.0) Required hospitalisation17 (11.3)13 (8.8) Prolonged hospitalisation0 (0.0)0 (0.0) Other3 (2.0)1 (0.7)Infections and infestations51 (33.8)51 (34.5) Viral upper respiratory tract infection17 (11.3)20 (13.5) Sinusitis0 (0.0)8 (5.4) Bronchitis5 (3.3)5 (3.4) Influenza5 (3.3)1 (0.7) Upper respiratory tract infection5 (3.3)3 (2.0) Urinary tract infection4 (2.6)4 (2.7) Gastroenteritis4 (2.6)2 (1.4) Pneumonia4 (2.6)3 (2.0) Cystitis3 (2.0)2 (1.4) Pharyngitis3 (2.0)2 (1.4)Respiratory, thoracic and mediastinal disorders46 (30.5)42 (28.4) COPD33 (21.9)30 (20.3) Dyspnoea7 (4.6)2 (1.4) Cough4 (2.6)2 (1.4)Nervous system disorders11 (7.3)6 (4.1) Headache5 (3.3)1 (0.7)Cardiac disorders7 (4.6)7 (4.7) Atrial fibrillation3 (2.0)1 (0.7)Vascular disorders8 (5.3)5 (3.4) Hypertension6 (4.0)3 (2.0)Gastrointestinal disorders26 (17.2)12 (8.1) Nausea4 (2.6)0 (0.0) Diarrhoea3 (2.0)2 (1.4) Vomiting3 (2.0)2 (1.4)A patient may be counted in more than one seriousness criterion. Percentages are calculated using total number of patients per treatment as the denominatorAE, adverse event; COPD, chronic obstructive pulmonary disease

The incidence of respiratory events was similar between the two treatment arms, occurring in 46 (30.5%) patients in the tiotropium arm and 42 (28.4%) patients in the tiotropium/olodaterol arm.

Discussion {#Sec19}
==========

Long-acting bronchodilators remain a key first-line therapy for COPD maintenance \[[@CR8], [@CR27]\], but many patients remain symptomatic on monotherapy \[[@CR9]--[@CR13]\]. This post hoc analysis focused on a subset of patients from the TONADO and OTEMTO studies with moderate-to-severe COPD who were treated with only LAMA monotherapy at baseline \[[@CR10], [@CR22]\]. Patients were excluded if they were currently on any other maintenance treatment. After 12 weeks, optimisation of treatment with tiotropium/olodaterol dual-bronchodilator therapy provided greater improvements in lung function (trough FEV~1~), health status (SGRQ) and dyspnoea severity (TDI) compared with continuing LAMA monotherapy. These results support treatment escalation from LAMA monotherapy to dual-bronchodilator treatment (as recommended in the GOLD management strategy \[[@CR8]\]) to optimise lung function, achieve better symptom control and improve patient quality of life.

We observed a greater likelihood of achieving an MCID in at least one of the outcomes (i.e., any trough FEV~1~, SGRQ or TDI improvements) in patients treated with tiotropium/olodaterol compared with patients treated with tiotropium monotherapy (odds ratio 2.43 ± 0.77, indicating a relative increase of 143% in the likelihood of achieving an FEV~1~, TDI or SGRQ response with tiotropium/olodaterol versus tiotropium; *P* = 0.0046). Data from the current analysis are consistent with the results from the overall populations reported in the individual study publications, suggesting that the benefits of tiotropium/olodaterol compared with tiotropium are observed across a range of COPD patients, including those previously treated with LAMA monotherapy prior to study entry \[[@CR10], [@CR22]\].

Despite the effectiveness shown with LAMA or LABA monotherapy, many patients remain symptomatic on these treatments \[[@CR9]--[@CR13]\], which can in turn impact daily living activities. Avoidance of physical activity to prevent dyspnoea can lead to deconditioning, thus further reducing patient activity and causing a downward spiral associated with worse patient outcomes \[[@CR28], [@CR29]\]. Patients with COPD who have some level of regular physical activity have lower risks of COPD-related hospital admissions and mortality \[[@CR29]\]. Patient evaluations should include exploration of symptoms by incorporating specialised tools, such as a short patient-centred questionnaire, to assess symptom severity, activity limitation and health-related quality of life \[[@CR30]\]. In clinical practice, the COPD Assessment Test is currently one of the most useful and practical questionnaires \[[@CR30]\]. Using the results from these tools, individual patient treatment plans should be reassessed and additional therapies added to optimise treatment \[[@CR12]\].

In support of the current study, similar findings have been shown in other studies comparing LAMA monotherapy with LAMA/LABA in patients with COPD \[[@CR2], [@CR19], [@CR20], [@CR23], [@CR31]\]. In a recent systematic literature review and meta-analysis by Han et al. \[[@CR32]\], patients treated with LAMA/LABA showed a 0.127 l (95% CI 0.108, 0.145; *P* \< 0.01) improvement in FEV~1~ area under the time curve 0--3 h post-dose at 12 weeks versus tiotropium. LAMA/LABA therapy also significantly improved the SGRQ total score at 12 weeks compared with tiotropium (improvement of 1.87 points; 95% CI − 2.72, − 1.02; *P* \< 0.01) and increased the SGRQ responder rate by 19% \[[@CR32]\]. However, the studies in this meta-analysis included patients on different background therapies, such as ICS, which could influence the overall results \[[@CR32]\]. In the current analysis, the confounding effects of previous therapies are removed, enabling a cleaner comparison of the impact of escalation from one bronchodilator to two bronchodilators and indicating significant improvements in trough FEV~1~, SGRQ and TDI after 12 weeks with tiotropium/olodaterol compared with tiotropium monotherapy.

Post hoc analyses of clinical trials have been conducted comparing LAMA/LABA combinations to long-acting bronchodilator monotherapies and also in various patient subgroups, including 'treatment-naïve' COPD patients who were previously not receiving any inhaled maintenance treatment. These analyses have shown similar results to the overall study population, with additional benefits for LAMA/LABA treatment across a range of lung function endpoints and patient-reported outcomes \[[@CR33]--[@CR36]\]. Such analyses have been used to provide evidence in the debate of whether to start COPD therapy with a LAMA/LABA or monotherapy \[[@CR33]--[@CR36]\]. The current analysis utilises large clinical trial data sets to address a question that is relevant to clinical practice; namely, what is the clinical benefit of treatment escalation from LAMA to LAMA/LABA?

Donohue et al. reported that only approximately one-third of patients displayed a pronounced lung function response to both long-acting bronchodilator classes, highlighting the between-patient variation in response to different bronchodilators \[[@CR37]\]. The current analysis provides information from a large pooled data set for treatment escalation responses on lung function and patient-reported outcomes, and the responder analysis supports the escalation step from LAMA to LAMA/LABA. However, as in the study by Donohue et al. \[[@CR37]\], clinical benefit will vary between individuals.

Previously, some safety concerns have been raised with use of dual bronchodilation in COPD \[[@CR38]--[@CR40]\]. However, our analysis of the TONADO and OTEMTO studies identified comparable safety profiles for the tiotropium and tiotropium/olodaterol treatment arms, presenting no specific concerns and indicating that stepping up from monotherapy to dual therapy is not met with an adverse safety profile. This is in agreement with previous studies evaluating the safety of tiotropium/olodaterol \[[@CR2], [@CR9], [@CR10], [@CR22], [@CR41]--[@CR43]\]. In the individual studies, no increase in major adverse cardiac events was observed between tiotropium/olodaterol and its monocomponents \[[@CR10], [@CR41]\]. In a previous pooled analysis of TONADO and OTEMTO, the incidence of AEs was similar between treatment groups \[[@CR2]\]; in OTEMTO, more AEs leading to treatment discontinuation were present in the placebo groups compared with the treatment groups, while in TONADO, AEs were similar across the treatment groups, ranging from 73% to 77% \[[@CR2]\]. In a separate pooled analysis of these studies, no additional safety concerns were identified in older patients using tiotropium/olodaterol \[[@CR44]\].

The current analysis pools data from four clinical trials, representing a large, clinically relevant patient population and allowing analysis of patients with COPD who were using LAMA monotherapy at baseline. However, these results have limitations due to the post hoc nature of the analysis and are therefore not powered for statistical comparisons, but nevertheless provide clinical value in the absence of any prospective data. At baseline, significant differences between the treatment arms were identified for weight and smoking status, but sensitivity analyses controlling for these covariates did not alter the presented results. This analysis also focuses on a subgroup of patients from the original studies that may not be fully representative of a wider COPD population.

Conclusion {#Sec20}
==========

Stepping up treatment to once-daily tiotropium/olodaterol led to significant improvements in lung function, dyspnoea severity and health status compared with tiotropium alone in patients with COPD who were receiving LAMA therapy at baseline. This shows that patients benefitted from maximising bronchodilation and treatment optimisation with tiotropium/olodaterol. Dual bronchodilation could provide additional benefits for patients with COPD currently on LAMA monotherapy and can be considered at initiation of maintenance therapy for patients with COPD.
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